TICKERNERD
Menu
SGRYSGRYHealthcare · Medical Care Facilities

SGRY Stock Forecast: Surgery Partners, Inc. Price Predictions for 2026-2027

Last close, 14 Oct 2026
$15
+1.92% on the day

The 12 Wall Street analysts covering Surgery Partners, Inc. hold a median 12-month price target of $19 — +28.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 43 of 100 as at 14 Oct 2026 — in the lower half.

Market cap
$1.9B
Ticker Nerd rank
43 / 100
Median analyst target
$19
Analysts covering
12
Revenue$848.9M+2.7% y/y
Operating income$116.5M
Net income$29.7M
Free cash flow$37.5M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+8.2%
1M
+5.6%
YTD
−4.0%
1Y
−29.1%
From 52W high
−35.4%
From 52W low
+29.1%
$11
$23
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

SGRY stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Surgery Partners, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 14 Oct 2026
43 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
69
Accruals
66
Value
63
Revisions
53
Volatility
52
Size
35
Issuance
35
Momentum
34
Quality
34

Growth (69): Sales and profits are climbing, and climbing faster than before.

Quality (34): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

SGRY stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on SGRY, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$12$14$16$18$20$22$24Jan 26Apr 26Jul 26Oct 26SGRYHigh $24Median $19Low $14

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says12 analysts
9 Buy3 Hold0 Sell
Low $14Median $19High $24

The green dot is the last close — the median target sits +28.1% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 2 moved their price target up and 5 moved it down.

DateFirmActionRatingTarget
30 Sept 2026RBC CapitalReiteratesOutperform$19
18 Sept 2026TD CowenReiteratesBuy—
18 Sept 2026TD CowenReiteratesBuy$19
14 Sept 2026JP MorganMaintainsNeutral—
14 Sept 2026JP MorganMaintainsNeutral$14 → $15
11 Aug 2026Cantor FitzgeraldReiteratesOverweight$18
11 Aug 2026Cantor FitzgeraldReiteratesOverweight—
11 Aug 2026RBC CapitalMaintainsOutperform$20 → $19
11 Aug 2026RBC CapitalMaintainsOutperform—
11 Aug 2026TD CowenMaintainsBuy—
11 Aug 2026TD CowenMaintainsBuy$17 → $19
5 Mar 2026MizuhoMaintainsOutperform$19 → $17
5 Mar 2026MizuhoMaintainsOutperform—
5 Mar 2026TD CowenMaintainsBuy—
5 Mar 2026TD CowenMaintainsBuy$28 → $20
5 Mar 2026UBSMaintainsBuy—
5 Mar 2026UBSMaintainsBuy$29 → $21
4 Mar 2026RBC CapitalMaintainsOutperform$31 → $20
4 Mar 2026RBC CapitalMaintainsOutperform—
3 Mar 2026BarclaysMaintainsEqual-Weight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. SGRY appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

SGRY vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 14 Oct 2026, Surgery Partners, Inc. returned −29.1% against +17.5% for the S&P 500, dividends included.

SGRY vs S&P 500, last 12 monthsTotal return, rebased to 100
6080100120Jan 26Apr 26Jul 26Oct 26SGRYS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

SGRY analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
−21.7%
Analysts raising
0
Analysts cutting
3
Fundamentals

Surgery Partners, Inc. (SGRY) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
2956.0×

Cheaper than 1% of US stocks

Price / sales
0.6×

Cheaper than 79% of US stocks

Price / book
1.1×

Cheaper than 67% of US stocks

EV / EBITDA
11.6×

Cheaper than 31% of US stocks

Growth & margins
Revenue growth (YoY)
2.7%

Higher than 33% of US stocks

Earnings growth (YoY)
2.7%

Higher than 39% of US stocks

Gross margin
22.4%

Higher than 24% of US stocks

Operating margin
13.7%

Higher than 71% of US stocks

Net margin
−2.6%

Higher than 27% of US stocks

Returns & dividend
Return on equity
2.3%

Higher than 48% of US stocks

Return on assets
3.7%

Higher than 69% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Surgery Partners, Inc. (SGRY) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Surgery Partners, Inc. has a market value of $1.9B and an enterprise value of $7.5B.

  • Revenue in the twelve months to 30 June 2026: $3.4B. The latest quarter grew 2.7% year on year.

  • Net income over the same four quarters: $81.9M, a 2.4% net margin.

  • Diluted earnings per share, trailing twelve months: $−0.70.

  • Free cash flow in the twelve months to 30 June 2026: $187.6M.

  • Shares outstanding: 130.9M.

  • Trailing P/E: 2956.0×; forward P/E: 52.0× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Surgery Partners, Inc. employs 16,000 people — $210K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 14 Oct 2026

Data provided by Twelve Data

Peers

SGRY vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Care Facilities
CompanyMarket capTKN rank
SGRYSurgery Partners, Inc.$1.9B
43
ASTHAstrana Health, Inc.$1.9B
69
ARDTArdent Health, Inc.$1.7B
58
SNDASonida Senior Living, Inc.$1.7B
27
ADUSAddus HomeCare Corp.$2.2B
96
MDPediatrix Medical Group, Inc.$2.2B
99
BKDBrookdale Senior Living, Inc.$2.4B
73

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Surgery Partners, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest SGRY news & analysis

Surgery Partners (SGRY) Soars 15.7%: Is Further Upside Left in the Stock?

Zacks Investment Research · 23 Sept 2026positive

Surgery Partners (SGRY) shares surged 15.7% in the last session on higher-than-average trading volume. The stock's recent trend in earnings estimate revisions could potentially lead to further price increases in the near term.

Why it matters — A SGRY watcher would care because the stock's strong surge and positive earnings estimate revision trend may signal continued momentum for the company.

Surgery Partners: A 'Buy' After Idaho Falls Asset Divestment

Seeking Alpha · 23 Sept 2026positive

An analyst initiated coverage of Surgery Partners with a Buy rating, citing the sale of its Idaho Falls asset. The divestiture is described as reducing leverage, improving cash flow, shifting payor mix away from Medicaid, and simplifying the company's short-stay surgical business.

Why it matters — The divestment is presented as strengthening Surgery Partners' balance sheet and sharpening its business focus, which is relevant to those tracking its operational and financial trajectory.

Surgery Partners Completes Sale of Ownership Interests in Idaho Falls Facilities to Intermountain Health; Updates Guidance to Include Impact of the Transaction

GlobeNewsWire · 17 Sept 2026neutral

Surgery Partners announced it has completed the previously announced sale of its ownership interests in its Idaho Falls facilities to Intermountain Health. The company also updated its guidance to include the impact of the transaction.

Why it matters — This transaction and the accompanying guidance update reflect a change in Surgery Partners' asset portfolio and forward-looking financial outlook that investors tracking SGRY would want to account for.

Surgery Partners Director Teresa DeLuca Buys 11,250 Shares

The Motley Fool · 3 Sept 2026positive

Surgery Partners director Teresa DeLuca purchased 11,250 shares valued at approximately $161,000, bringing her total position to 68,093 shares. The buy was reported by The Motley Fool.

Why it matters — An insider purchase by a director can signal confidence in the company's prospects to SGRY watchers.

Likely ETF & Stock Winners From July Jobs Report

Zacks Investment Research · 11 Aug 2026neutral

Zacks Investment Research reported that weak July jobs data has raised hopes for Federal Reserve easing, putting health care and select retail ETFs and stocks in focus.

Why it matters — As a health-care company, Surgery Partners could be among the stocks viewed favorably in a potential Fed easing environment.

FAQ

Frequently asked questions about SGRY stock

What is the SGRY stock price forecast for 2026-2027?

The 12 Wall Street analysts covering Surgery Partners, Inc. have a median 12-month price target of $19, with estimates ranging from $14 to $24. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is SGRY stock a buy right now?

Of the 12 analysts covering Surgery Partners, Inc., 9 rate it a Buy, 3 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Surgery Partners, Inc. 43 out of 100 across roughly 4,600 US stocks as at 14 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank SGRY?

As at 14 Oct 2026, Surgery Partners, Inc. ranks 43 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (69 of 100).

Will SGRY stock go up?

No one can know that. What the data says: the median 12-month target from 12 analysts implies +28.1% from the last close, and Ticker Nerd's factor model ranks Surgery Partners, Inc. 43 out of 100 as at 14 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the SGRY stock forecast for 2030?

No analyst covering Surgery Partners, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SGRY are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $14 to $24 over the next 12 months.

How has SGRY stock performed over the past year?

Surgery Partners, Inc. returned -29.1% over the 12 months to 14 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Surgery Partners, Inc. do?

Surgery Partners Inc. is a healthcare services company that owns and operates a broad network of surgical facilities and related care services across the United States.

What is the latest news on SGRY?

The most recent item we track (Zacks Investment Research, 23 Sept 2026): "Surgery Partners (SGRY) Soars 15.7%: Is Further Upside Left in the Stock?". Surgery Partners (SGRY) shares surged 15.7% in the last session on higher-than-average trading volume. The stock's recent trend in earnings estimate revisions could potentially lead to further price increases in the near term.

Company

About Surgery Partners, Inc.

Surgery Partners Inc. is a healthcare services company that owns and operates a broad network of surgical facilities and related care services across the United States. The company focuses on outpatient and short-stay procedures delivered through ambulatory surgery centers and surgical hospitals, serving patients in specialties such as orthopedics, pain management, ophthalmology, gastroenterology, and general surgery. Its integrated model also includes anesthesia services, multi-specialty physician practices, diagnostic testing, urgent care facilities, and other ancillary services that support clinical operations. Surgery Partners Inc. plays a significant role in the outpatient care market by connecting providers, facilities, and supporting services within a coordinated healthcare delivery platform. Headquartered in Brentwood, Tennessee, the company serves a wide range of communities through locations in multiple states.

CEO Mr. J. Eric Evans · 16,000 employees · United States · https://www.surgerypartners.com